Literature DB >> 10725724

Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells.

U M Nagarajan1, A Peijnenburg, S J Gobin, J M Boss, P J van den elsen.   

Abstract

MHC class II deficiency or bare lymphocyte syndrome is a severe combined immunodeficiency caused by defects in MHC-specific regulatory factors. Fibroblasts derived from two recently identified bare lymphocyte syndrome patients, EBA and FZA, were found to contain novel mutations in the RFX-B gene. RFX-B encodes a component of the RFX transcription factor that functions in the assembly of multiple transcription factors on MHC class II promoters. Unlike RFX5- and RFXAP-deficient cells, transfection of exogenous class II transactivator (CIITA) into these RFX-B-deficient fibroblasts resulted in the induction of HLA-DR and HLA-DP and, to a lesser extent, HLA-DQ. Similarly, CIITA-mediated induction of MHC class I, beta2-microglobulin, and invariant chain genes was also found in these RFX-B-deficient fibroblasts. Expression of wild-type RFX-B completely reverted the noted deficiencies in these cells. Transfection of CIITA into Ramia cells, a B cell line that does not produce a stable RFX-B mRNA, resulted in induction of an MHC class II reporter, suggesting that CIITA overexpression may partially override the RFX-B defect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725724     DOI: 10.4049/jimmunol.164.7.3666

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.

Authors:  Wojciech Wiszniewski; Marie-Claude Fondaneche; Pascale Louise-Plence; Ada Prochnicka-Chalufour; Françoise Selz; Cappucine Picard; Françoise Le Deist; Jean-François Eliaou; Alain Fischer; Barbara Lisowska-Grospierre
Journal:  Immunogenetics       Date:  2003-01-16       Impact factor: 2.846

2.  Associations and interactions between bare lymphocyte syndrome factors.

Authors:  A M DeSandro; U M Nagarajan; J M Boss
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 3.  Expression of nonclassical MHC class Ib genes: comparison of regulatory elements.

Authors:  T Kevin Howcroft; Dinah S Singer
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study.

Authors:  Michal Krawczyk; Krzysztof Masternak; Madeleine Zufferey; Emmanuèle Barras; Walter Reith
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

5.  Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP.

Authors:  Meghan Bushway; Kelly A Cycon; Kathleen Mulvaney; Shawn P Murphy
Journal:  Immunogenetics       Date:  2009-12-19       Impact factor: 2.846

6.  Evolutionary conservation and characterization of the bare lymphocyte syndrome transcription factor RFX-B and its paralogue ANKRA2.

Authors:  Alyssa Bushey Long; Jeremy M Boss
Journal:  Immunogenetics       Date:  2005-01-18       Impact factor: 2.846

7.  Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome.

Authors:  N Nekrep; M Geyer; N Jabrane-Ferrat; B M Peterlin
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

8.  Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter.

Authors:  Han Chen; Carolyn A Gilbert; John A Hudson; Sophia C Bolick; Kenneth L Wright; Janet F Piskurich
Journal:  Mol Immunol       Date:  2006-06-12       Impact factor: 4.407

9.  Distinct transcriptional pathways regulate basal and activated major histocompatibility complex class I expression.

Authors:  T Kevin Howcroft; Aparna Raval; Jocelyn D Weissman; Anne Gegonne; Dinah S Singer
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

10.  Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.

Authors:  Thomas Prod'homme; Benjamin Dekel; Giovanna Barbieri; Barbara Lisowska-Grospierre; Rina Katz; Dominique Charron; Catherine Alcaide-Loridan; Shimon Pollack
Journal:  Immunogenetics       Date:  2003-10-22       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.